ASP同位素公司美股招股说明书（2025-10-16版）

Prospectus Supplement(To Prospectus dated October 14, 2025) We are offering shares of our common stock, par value $0.01 per share, having an aggregate indicative offering price of $210,300,405,pursuant to this prospectus supplement and the aprospectus. The underwriters have agreed to purchase the common stock from us at a price of $11.65per share, which will result in approximately $200.0 millionof proceeds to us, before offeassuming no exercise by the underwriters of the option described below. The underwriters propose to offer the shares of common stock from time to time for sale in one or more transactiothe existing trading market for our common stock, in negotiated transactions or otherwise at market prices prevailing at the time of sale, at prices related to prevailing market prices orprices, subject to receipt and acceptance by it and subject to its right to reject any order in whole or in part. See “Underwriting.” We have granted the underwriters an option for a period of 30 days from the date of this prospectus supplement to purchase up to$31,545,048 ofadditional shares of common stock, lessdiscounts and commissions. If the underwriters exercise the option in full, the total proceeds to us from this offering, before expenses, will beapproximately $230.0 million. Investing in our securities involves a high degree of risk. See “Risk Factors” on page S-10 of this prospectus supplement, on page 4 of the accompanying prospectus and in our filU.S. Securities and Exchange Commission that are incorporated by reference into this prospectus supplement and the accompanying prospectus. Neither the U.S. Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus struthful or complete. Any representation to the contrary is a criminal offense. The underwriters expect to deliver the shares of common stock to purchasers on or aboutOctober 16, 2025. Cantor Lucid Cap TABLE OF CONTENTS Prospectus SupplementAbout This Prospectus SupplementProspectus Supplement SummaryThe OfferingRisk FactorsSpecial Note Regarding Forward-Looking StatementsUse of ProceedsDividend PolicyCapitalizationDilutionUnderwritingLegal MattersExpertsWhere You Can Find More InformationIncorporation by ReferencePROSPECTUSABOUT THIS PROSPECTUSTHE COMPANYRISK FACTORSSPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTSUSE OF PROCEEDSDESCRIPTION OF CAPITAL STOCKDESCRIPTION OF DEBT SECURITIESDESCRIPTION OF WARRANTSDESCRIPTION OF UNITSPLAN OF DISTRIBUTIONLEGAL MATTERSEXPERTSINFORMATION INCORPORATED BY REFERENCEWHERE YOU CAN FIND MORE INFORMATION ABOUT THIS PROSPECTUS SUPPLEMENT This prospectus supplement is part of an automatic shelf registration statement that we have filed with the Securities and Exchange Commission, or “SEC,” as a “well-known seaas such term is defined inRule 405under theSecurities Act of 1933, as amended, or the“Securities Act,” utilizing a “shelf” registration process. This prospectus supplement and the accompanying prospectus relate to the offering of our common stock. Before buying any shares of common stock that we are offering, wcarefully read this prospectus supplement and the accompanying prospectus, together with the information incorporated by reference as described under the headings “Where You CaInformation” and “Incorporation by Reference” in this prospectus supplement. These documents contain important information that you should consider when making your investment decis This document is in two parts. The first part is this prospectus supplement, which describes the terms of this offering of common stock and adds to and updates information coaccompanying prospectus and the documents incorporated by reference into this prospectus supplement and the accompanying prospectus. The second part, the accompanying prospectus,documents incorporated by reference therein, provides more general information, some of which may not apply to this offering. Generally, when we refer to this prospectus, we are referringof this document combined. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, and the information contained in the aprospectus or in any document incorporated by reference that was filed with the SEC, before the date of this prospectus supplement, on the other hand, you should rely on the informprospectus supplement. If any statement in one of these documents is inconsistent with a statement in another document having a later date, the statement in the document having the lateror supersedes the earlier statement. You should rely only on the information contained in or incorporated by reference in this prospectus supplement, the accompanying prospectus and in any free writing prospectusauthorized for use in connection with this offering. Neither we nor any of the underwriters have authorized anyone to provide you with different information. If anyone provides yo